Interactive Brokers Appointed International Broker for Sinopac Securities
16.2.2023 09:00:00 EET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced its appointment as the primary international broker for Sinopac Securities today. Institutional and retail clients of Sinopac can trade US stocks, ETFs, and Fixed Income instruments while also accessing over 90 stock markets worldwide through Interactive Brokers. This initiative between Interactive Brokers LLC and Sinopac strengthens Interactive Brokers’ footprint in the APAC region and adds Taiwan to the over 200 countries and territories worldwide where the company services clients.
“We are pleased to work with Sinopac and bring Interactive Brokers’ global trading capabilities and expertise to Taiwan,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “We recognize the advantage of working with a leading broker with local experience and look forward to serving the needs of this important market and its investors.”
Taiwanese investors will benefit from Interactive Brokers’ powerful trading platforms and advanced technology and tools. Interactive Brokers offers clients the ability to trade fractional shares of eligible US and European stocks as well as ETFs and can accommodate over 100 order types, including algorithmic trading, which is currently unavailable through other brokers in Taiwan. Clients can trade select US ETFs 23½ hours a day, five days a week through Overnight Trading Hours on the IBKR Eos ATS (“IBEOS”). With Overnight Trading Hours, investors across Asia can access US Equity Markets during their trading day and respond to market-moving news at almost any time. The collaboration with Sinopac also enables clients of Interactive Brokers to trade Taiwanese stocks through Sinopac Securities.
Introducing Brokers worldwide use Interactive Brokers’ Prime Broker services to help manage their businesses with efficiency and serve their clients at a lower cost. Through Interactive Brokers, Introducing Brokers can reduce their operational, brokerage, and clearing costs while gaining electronic market access worldwide with the company’s professional, white-branded trading technology. Interactive Brokers’ turnkey solution covers trading, clearing, reporting, and billing and provides the following advantages:
- Support for global regulatory reporting
- Account funding and trading in up to 26 currencies
- Access to stocks, options, futures, currencies, bonds, and funds in over 150 markets from a single unified platform
- No ticket charges, no minimums, and no technology, software, platform, or reporting fees
- Free client relationship management tools
For additional information about Interactive Brokers’ Introducing Broker platform, please visit:
US and Countries Served by IB LLC: https://www.interactivebrokers.com/en/accounts/broker.php
Canada: https://www.interactivebrokers.ca/en/accounts/broker.php
UK: https://www.interactivebrokers.co.uk/en/accounts/broker.php
Western Europe: https://www.interactivebrokers.ie/en/accounts/broker-ie.php
Central Europe: https://www.interactivebrokers.hu/en/accounts/broker-hu.php
Hong Kong: https://www.interactivebrokers.com.hk/en/accounts/broker.php
Singapore: https://www.interactivebrokers.com.sg/en/accounts/broker.php
India: https://www.interactivebrokers.co.in/en/accounts/broker.php
Australia: https://www.interactivebrokers.com.au/en/accounts/broker.php
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 150 markets in numerous countries and currencies from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005686/en/
Contact information
Interactive Brokers Group, Inc
Katherine Ewert, media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
